Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04236232
Other study ID # Subclinical Hypothyroidism
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 1, 2020
Est. completion date June 1, 2021

Study information

Verified date January 2020
Source Assiut University
Contact Randa Mahrous Roushdy
Phone 01288537350
Email randama7rous@yahoo.co
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research aims to evaluate the relation between SCH and cardiovascular System by assessment of lipid profile and carotid intima-media thickness (CIMT), as a marker of atherosclerosis, and endothelial function.


Description:

Subclinical hypothyroidism (SCH) is defined as a condition that characterized by elevated serum thyroid-stimulating hormone (TSH) concentrations (TSH: >4.5 mu/l), while circulating thyroxine (T4) and tri- iodothyronine (T3) levels remain within the normal range.

Depending on the extent of serum TSH elevation, SCH can be divided into Mild (where the concentration of serum TSH is in the range of 4.5-9 mU/l) Severe (TSH≥10 mU/l) SCH. Mild SCH constitutes ~75% of the total number of patients with SCH. The incidence of SCH varies between 5 and 10 % depending upon the gender, age, more frequent in women than in men, with increasing prevalence with advanced age in both sexes The consequences of SCH are variable at several levels and may depend on the duration and the degree of increasing level of the serum TSH. However, a number of important questions about SCH remain, including whether it increases cardiovascular (CVS) risk or not.

SCH has many causes the most common (60% to 80%) is chronic autoimmune thyroiditis associated with the presence of circulating anti-thyroid peroxidase antibodies(TPOAb) that are the most sensitive serological test for thyroid autoimmunity and/or antithyroglobulin Antibodies(TgAb).

The association between subclinical hypothyroidism (SCH) and cardiovascular disease has received increasing attention in recent years.

Thyroid hormones exert a direct effect on the heart and blood vessels. The deficit of these hormones leads to functional disorders of the Cardiovascular System (CVS) such as changes in cardiac frequency, cardiac output, left ventricular diastolic dysfunction, and reduced resting and exceptional systolic function.

Vascular abnormalities, such as increased vascular resistance, arterial stiffness, endothelial dysfunction, that is considered to be an early step in the development and progression of atherosclerosis.

The early changes in patients with SCH is alteration in lipid profile that could be a contributing factor for the risk of atherosclerosis, hyperlipidemia is one of the common causal factors of endothelial dysfunction.

Elevation of TSH has a positive correlation with serum total cholesterol (TC), triglycerides, LDL cholesterol (LDL-C), and a negative correlation to HDL cholesterol.

Some studies found significant lipid profile changes in patients with SCH, some others did not.

Atherosclerosis is a diffuse, degenerative disease of the arteries that results in the formation of porridge-like lipid deposit plaques in the great arterial wall, and accounts for the majority of cardiovascular disease incidence. Therefore, this association is the first to be assessed for the link between SCH and cardiovascular disease.

Progression of atherosclerosis features a chronic unresolved inflammatory response, leading to stenosis, embolization and thrombosis, since atherosclerosis is a chronic disease, to observe the whole pathogenesis in one single investigation would require a long time of study .Thus, endothelial dysfunction, as one of the earliest signs for atherosclerosis, could be most frequently observed in clinical investigation Assessment of endothelial dysfunction, being an early biomarker, is helpful in predicting cardiovascular risk by Carotid artery intima-media thickness (CIMT) measurement that has increasingly been used as a marker of atherosclerosis in many studies.

Evidence supporting the correlation between SCH and atherosclerosis has been accumulating:

The first study regarding the associated cardiovascular risk in patients with SCH was the long-time large cross-sectional Rotterdam study in the Netherlands, which showed an increased risk for atherosclerosis and prevalence of myocardial infarction among female patients with SCH aged >55 years. Velkoska and his colleagues who reported that SCH is associated with increase in CIMT and presence of carotid plaques independent of traditional atherosclerosis risk factors, Onder et al. who showed lack of a significant difference in CIMT between over and subclinical hypothyroid, indicating that the inflammation leading to increased CIMT starts in the subclinical phase .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date June 1, 2021
Est. primary completion date May 1, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- All healthy adult who will be diagnosed as SCH along with age =18 & gender-matched healthy relatives with normal thyroid function will be screened for evidence of high cardiovascular risk.

Exclusion Criteria:

- Hypo or hyper-thyroidism, Diabetes, Hypertension, cardiovascular disease, smokers, pregnant and lactating women.

Patients who had been treated with anti-thyroid drugs, radio iodine therapy or thyroxin hormone supplement or who had under gone thyroid surgery, those with a history of thyroid cancer or head and neck malignancies.

Those with history of drug use such as Contraceptive pill, Anti-depressant drugs, Corticosteroids, Anti arrhythmic drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Thyroid function
Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography?ECG, Ultrasonography of Carotid artery

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (2)

Floriani C, Gencer B, Collet TH, Rodondi N. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Eur Heart J. 2018 Feb 14;39(7):503-507. doi: 10.1093/eurheartj/ehx050. — View Citation

Sun J, Yao L, Fang Y, Yang R, Chen Y, Yang K, Tian L. Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. Int J Endocrinol. 2017;2017:8130796. doi: 10.1155/2017/8130796. Epub 2017 Aug 31. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Our data will reveale that SCH is associated with increase in CIMT and presence of carotid plaques,and these patients have an increased risk of cardiovascular disease compared with healthy patients. The study Will include 50 patients with newly diagnosed SCH, and 50 healthy controls. Body mass index (BMI), TSH, fT4, lipids, blood pressure, mean and maximum carotid intima-media thickness (CIMT) will be determined in all participants. Baseline
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05975866 - The Effects of an Anti-inflammatory Diet With or Without Curcumin Supplementation on Anthropometric Measurements, Concentrations of Thyroid Hormones, Anti-TPO, and Systemic Inflammation in Plasma and NFK-B in Peripheral Blood Mononuclear Cells in Patients With Hashimato N/A
Not yet recruiting NCT05334771 - Early Detection of Endolymphatic Hydrops in Hypothyroid Patients
Withdrawn NCT01707056 - The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma N/A
Completed NCT00094237 - Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke N/A
Recruiting NCT06015620 - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed NCT03612908 - TSHβX1 and D2 THR92ALA in Pregnancy
Completed NCT04782856 - Energy Metabolism in Thyroidectomized Patients Phase 2
Completed NCT01921452 - Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit Phase 4
Completed NCT01197183 - Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France N/A
Recruiting NCT05247476 - Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. Phase 4
Recruiting NCT03754621 - Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey
Completed NCT02959827 - Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
Completed NCT04124705 - A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Phase 2
Withdrawn NCT02577367 - Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding Phase 4
Completed NCT04098991 - Improving White Matter Integrity With Thyroid Hormone
Not yet recruiting NCT03257566 - Hypothyroidism in Patients With Type 1 Diabetes N/A
Terminated NCT02567877 - Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?
Completed NCT02280330 - Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months Phase 4
Completed NCT00403390 - Generic vs. Name-Brand Levothyroxine N/A
Not yet recruiting NCT06096454 - Effect of Life Style Modification and Metformin on Hypothyroidism With Insulin Resistance Phase 4